EnWave Declares Test Results For Antibodies Using freezeREV Dehydration Technology

EnWave has announced that it has dried three different antibodies in the company’s prototype freezeREV vial dehydration technology. Results from the study showed no detectable visual difference between freezeREV-dried and freeze dried samples when examined with the SDS-PAGE electrophoresis method.

The indication of the molecular weight was similar between the two dried samples and liquid antibodies.

The freezeREV prototype has been designed to reduce the drying time and temperature exposure from days, to minutes or hours, creating the potential for a high-speed, cost effective dehydration technology.

The three polyclonal antibodies used in the study were derived from chicken, rabbit and bovine blood serum.

Tim Durance, director, chairman and co- CEO of EnWave, said: “These are exciting results for the company as we are seeing the potential of this technology in a new area of biopharmaceuticals and biomaterials. We have tested a variety of proteins in the past, but antibody dehydration could open up a huge new market for EnWave, and this would compliment our existing research into vaccine dehydration.”

EnWave has initiated a search for an industry partner with whom to expand testing for both polyclonal and monoclonal antibody products with the goal of proving that freezeREV dehydration technology can be developed into a commercially viable method.